TScan announces first patient dosed in Phase 1 study of TSC-100, TSC-101

TScan Therapeutics announced that the first patient has been dosed in its Phase 1 umbrella trial of TSC-100 and TSC-101 targeting minor histocompatibility antigens HA-1 and HA-2, respectively, to treat residual leukemia and prevent relapse following hematopoietic cell transplantation, HCT, using reduced intensity conditioning, RIC, in patients with acute myeloid leukemia, myelodysplastic syndromes, MDS, or acute lymphocytic leukemia, ALL. The patient was treated with TSC-101, the first clinical cell therapy product targeting MiHA HA-2. "Dosing the first patient in our hematologic malignancies program marks an important milestone for TScan and a new era for TCR-T cell therapy," said David Southwell, President and Chief Executive Officer. "While remarkable clinical outcomes have been achieved through HCT treatment in hematologic oncology, the remaining high relapse rates leading to mortality risk mean that next-generation approaches are necessary. Treatment of the first-ever patient with TSC-101 offers the potential to overcome the toxicity associated with myeloablative conditioning to unlock the full potential of transplant therapy for hematologic cancers. We are excited about the enthusiasm of clinical investigators and the opening of additional clinical sites."